Imunon Inc (NASDAQ:IMNN) announced positive results from their phase 2 Ovation 2 study, showing significant improvement in ...
GlobalData on MSN1d
Imunon reports immunogenicity and safety data from DNA plasmid vaccine trialImunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN ...
Q4 2024 Results Conference Call February 26, 2025 11:00 AM ETCompany ParticipantsPeter Vozzo - ICR Healthcare, IRStacy Lindborg ...
IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase ...
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® ...
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine ® technology IMNN-101 induced 2- to 4-fold increase in ...
Results from OVATION 2 Study continue to validate TheraPlas® technology, demonstrating DNA-mediated production of key anti-cancer immune cytokines following treatment IMNN-001 continues to show ...
LAWRENCEVILLE, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company entering a pivotal Phase 3 trial of its DNA-mediated immunotherapy, today announced new ...
New Jersey, USA-based Imunon announced new translational data from the Phase II OVATION 2 Study of IMNN-001, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback